Interferon beta normalizes suppressor cell function in dysimmune neuropathies.
We found a defective suppressor cell function in vitro both in idiopathic chronic inflammatory demyelinating polyneuropathy and in paraproteinemic neuropathy with antibodies to sulfated glucuronyl paragloboside. In the presence of interferon beta, suppressor cell function was normalized. Our results suggest that a decreased suppressor cell function plays a pathogenetic role in dysimmune neuropathies. Interferon beta might represent an adjunctive therapy in CIDP both acting on a defective blood-nerve barrier and normalizing an otherwise defective suppressor cell function.
De Luca
Giovanna
G
Center for Neuromuscular Diseases, Department of Oncology and Neurosciences of the University of Chieti, Policlinico Clinicizzato `Colle Dell'Ara', I-66013 Chieti, Italy.
Lugaresi
Alessandra
A
Center for Neuromuscular Diseases, Department of Oncology and Neurosciences of the University of Chieti, Policlinico Clinicizzato `Colle Dell'Ara', I-66013 Chieti, Italy.
Iarlori
Carla
C
Center for Neuromuscular Diseases, Department of Oncology and Neurosciences of the University of Chieti, Policlinico Clinicizzato `Colle Dell'Ara', I-66013 Chieti, Italy.
Marzoli
Fabio
F
Center for Neuromuscular Diseases, Department of Oncology and Neurosciences of the University of Chieti, Policlinico Clinicizzato `Colle Dell'Ara', I-66013 Chieti, Italy.
Uncini
Antonino
A
Center for Neuromuscular Diseases, Department of Oncology and Neurosciences of the University of Chieti, Policlinico Clinicizzato `Colle Dell'Ara', I-66013 Chieti, Italy.
Gambi
Domenico
D
Center for Neuromuscular Diseases, Department of Oncology and Neurosciences of the University of Chieti, Policlinico Clinicizzato `Colle Dell'Ara', I-66013 Chieti, Italy.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000097:blood; D002648:Child; D003711:Demyelinating Diseases / Q000276:immunology / Q000628:therapy*; D005260:Female; D005915:Globosides / Q000276:immunology; D006801:Humans; D007075:Immunoglobulin M / Q000097:blood; D016899:Interferon-beta / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D018992:Myelin-Associated Glycoprotein / Q000276:immunology; D010265:Paraproteinemias / Q000276:immunology / Q000628:therapy*; D010523:Peripheral Nervous System Diseases / Q000276:immunology / Q000628:therapy*; D011115:Polyneuropathies / Q000276:immunology / Q000628:therapy; D011994:Recombinant Proteins / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D005915:Globosides; D007075:Immunoglobulin M; D018992:Myelin-Associated Glycoprotein; D011994:Recombinant Proteins; C051917:sulfate-3-glucuronyl paragloboside; D016899:Interferon-beta